EP3092250A4 - Polynukleotide zur in-vivo-erzeugung von antikörpern - Google Patents

Polynukleotide zur in-vivo-erzeugung von antikörpern Download PDF

Info

Publication number
EP3092250A4
EP3092250A4 EP15735068.7A EP15735068A EP3092250A4 EP 3092250 A4 EP3092250 A4 EP 3092250A4 EP 15735068 A EP15735068 A EP 15735068A EP 3092250 A4 EP3092250 A4 EP 3092250A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
antibodies
vivo production
vivo
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15735068.7A
Other languages
English (en)
French (fr)
Other versions
EP3092250A1 (de
Inventor
Joseph Beene BOLEN
Axel Bouchon
Giuseppe Ciaramella
Eric Yi-Chun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
Moderna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moderna Therapeutics Inc filed Critical Moderna Therapeutics Inc
Publication of EP3092250A1 publication Critical patent/EP3092250A1/de
Publication of EP3092250A4 publication Critical patent/EP3092250A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15735068.7A 2014-01-08 2015-01-08 Polynukleotide zur in-vivo-erzeugung von antikörpern Withdrawn EP3092250A4 (de)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US201461924781P 2014-01-08 2014-01-08
US201461924812P 2014-01-08 2014-01-08
US201461924770P 2014-01-08 2014-01-08
US201461924783P 2014-01-08 2014-01-08
US201461924850P 2014-01-08 2014-01-08
US201461924787P 2014-01-08 2014-01-08
US201461924811P 2014-01-08 2014-01-08
US201461924841P 2014-01-08 2014-01-08
US201461924767P 2014-01-08 2014-01-08
US201461924820P 2014-01-08 2014-01-08
US201461924819P 2014-01-08 2014-01-08
US201461924773P 2014-01-08 2014-01-08
US201461924791P 2014-01-08 2014-01-08
US201461924804P 2014-01-08 2014-01-08
US201461924817P 2014-01-08 2014-01-08
US201461924754P 2014-01-08 2014-01-08
US201461924763P 2014-01-08 2014-01-08
US201461924795P 2014-01-08 2014-01-08
US201461924775P 2014-01-08 2014-01-08
US201461924846P 2014-01-08 2014-01-08
US201461924805P 2014-01-08 2014-01-08
US201461924776P 2014-01-08 2014-01-08
US201461924774P 2014-01-08 2014-01-08
US201461924802P 2014-01-08 2014-01-08
US201461924779P 2014-01-08 2014-01-08
US201461924827P 2014-01-08 2014-01-08
US201461924799P 2014-01-08 2014-01-08
US201461924810P 2014-01-08 2014-01-08
US201461924807P 2014-01-08 2014-01-08
US201461924768P 2014-01-08 2014-01-08
US201461924834P 2014-01-08 2014-01-08
US201461993715P 2014-05-15 2014-05-15
PCT/US2015/010547 WO2015105926A1 (en) 2014-01-08 2015-01-08 Polynucleotides for the in vivo production of antibodies

Publications (2)

Publication Number Publication Date
EP3092250A1 EP3092250A1 (de) 2016-11-16
EP3092250A4 true EP3092250A4 (de) 2017-05-24

Family

ID=53524318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15735068.7A Withdrawn EP3092250A4 (de) 2014-01-08 2015-01-08 Polynukleotide zur in-vivo-erzeugung von antikörpern

Country Status (2)

Country Link
EP (1) EP3092250A4 (de)
WO (1) WO2015105926A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B1 (de) 2010-10-01 2020-12-30 ModernaTX, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833923A4 (de) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modifizierte polynukleotide zur herstellung von proteinen
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2971165A4 (de) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Entfernung von dna-fragmenten in mrna-herstellungsverfahren
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP3578663A1 (de) 2013-03-15 2019-12-11 ModernaTX, Inc. Herstellungsverfahren zur herstellung von rna-transkripten
EP2971161B1 (de) 2013-03-15 2018-12-26 ModernaTX, Inc. Nukleinsäurereinigung
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016011222A2 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
EP3171895A1 (de) * 2014-07-23 2017-05-31 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von intrabodys
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP4310503A3 (de) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Verfahren im zusammenhang mit biologika
US10532109B2 (en) 2016-05-18 2020-01-14 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-DNA chimeras for treatment of HER overexpressing cancers
WO2018009838A1 (en) 2016-07-07 2018-01-11 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
WO2018021188A1 (ja) * 2016-07-26 2018-02-01 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
EP3541474A4 (de) * 2016-11-16 2020-08-05 University Of Maryland, Baltimore Verfahren zur behandlung von knochenerkrankungen
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
EP4172194A1 (de) * 2020-07-31 2023-05-03 CureVac SE Nukleinsäurecodierte antikörpermischungen
EP4277929A1 (de) * 2021-01-14 2023-11-22 Translate Bio, Inc. Verfahren und zusammensetzungen zur abgabe von mrna-codierten antikörpern
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
KR20240049810A (ko) 2021-09-03 2024-04-17 큐어백 에스이 핵산 전달용 신규 지질 나노입자
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20130195867A1 (en) * 2007-01-09 2013-08-01 Curevac Gmbh Rna-coded antibody
US20130196377A1 (en) * 2011-12-26 2013-08-01 Samsung Electronics Co., Ltd. Protein complex and method of preparing same
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014152774A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015105926A1 *

Also Published As

Publication number Publication date
EP3092250A1 (de) 2016-11-16
WO2015105926A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EP3092250A4 (de) Polynukleotide zur in-vivo-erzeugung von antikörpern
EP3212231A4 (de) Anti-tim-3*-antikörper
EP3212229A4 (de) Anti-tim-3*-antikörper
EP3240564A4 (de) Verfahren zur herstellung langwirkender ctp-modifizierter polypeptide
EP3192864A4 (de) Verfahren zur herstellung von zerebellarem vorläufergewebe
EP3166931A4 (de) Verbessertes verfahren zur herstellung von exametazim
EP3237195A4 (de) Verfahren zur herstellung von pressware
EP3119806A4 (de) Il-21-antikörper
HUP1400114A2 (en) Method for the production of peptides
EP3177650A4 (de) Anti-ceramit-antikörper
EP3181709A4 (de) Stahlbandherstellungsvorrichtung
EP3151857A4 (de) Anti-blys-antikörper
EP3112463A4 (de) Neuartige anti-presepsin-antikörper
IL248267A0 (en) A process for preparing converted cycloserines
EP3233120A4 (de) Il-21-antikörper
EP3138903A4 (de) Zellen zur herstellung eines humanen antikörpers
HUE055687T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
EP3147369A4 (de) Verfahren zur herstellung eines fibroinartigen proteins
EP3127943A4 (de) Verfahren zur herstellung von nanopartikeln
EP3227246B8 (de) Oxy-calcinationsverfahren
EP3107883A4 (de) Verfahren zur herstellung von hydrochlorfluorolefinen
EP3182981A4 (de) Verfahren zur herstellung von isomaltooligosacchariden
EP3099655A4 (de) Verfahren zur herstellung von hydrochlorfluorolefinen
EP3242937A4 (de) Verfahren zur herstellung von abienol
IL241974A0 (en) Process for making erlotinib

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170424

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 19/34 20060101ALI20170418BHEP

Ipc: C07K 16/18 20060101AFI20170418BHEP

Ipc: A61K 39/395 20060101ALI20170418BHEP

Ipc: C07K 16/28 20060101ALI20170418BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MODERNATX, INC.

17Q First examination report despatched

Effective date: 20190802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20191017